Last update 18 Nov 2026

Icosapent Ethyl

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(all-Z)-5,8,11,14,17-Eicosapentaenoic acid ethyl ester, all-cis-ethyl 5,8,11,14,17-icosapentaenoate, cis-Eicosapentaenoic acid ethyl ester
+ [35]
Target
Action
agonists
Mechanism
PPARα agonists(Peroxisome proliferator-activated receptor α agonists)
Active Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
Japan (05 Oct 1994),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC22H34O2
InChIKeySSQPWTVBQMWLSZ-AAQCHOMXSA-N
CAS Registry86227-47-6

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetes Mellitus
European Union
21 Oct 2022
Diabetes Mellitus
Iceland
21 Oct 2022
Diabetes Mellitus
Liechtenstein
21 Oct 2022
Diabetes Mellitus
Norway
21 Oct 2022
Pain
South Korea
21 Feb 2022
Ulcer
South Korea
21 Feb 2022
Cardiovascular Diseases
United States
13 Dec 2019
Hypertriglyceridemia
United States
26 Jul 2012
Arteriosclerosis Obliterans
Japan
15 Oct 1998
Hyperlipidemias
Japan
05 Oct 1994
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Colonic CancerPhase 3
United Kingdom
02 May 2018
Liver metastasesPhase 3
United Kingdom
02 May 2018
Huntington DiseasePhase 3
United States
01 Sep 2005
Huntington DiseasePhase 3
Canada
01 Sep 2005
Metabolic Dysfunction Associated SteatohepatitisPhase 2
United States
01 Jun 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
-
81
Icosapent ethyl (IPE) 4g/d
aanxfqzqnn(gtqhapvfha) = iyfspdldmj ckaulqsynu (wukitvmdpb )
Positive
01 Sep 2026
Not Applicable
46
abiwgfwluk(wzzickwyme) = wczrqledzy tnkxdkekbl (ztbrkbhrsr )
Positive
24 Apr 2026
Phase 3
8,174
yvdmbmxxnf(afhakuffxr): HR = 0.55 (95.0% CI, 0.3 - 1.01), P-Value = 0.05
Positive
22 Sep 2025
Placebo
Phase 3
8,172
ikcjbnrxyw(rqzvtrcpsg) = kfqsawwruj ofzpvgmsft (lhixkllsil )
Positive
15 Sep 2025
Placebo
ikcjbnrxyw(rqzvtrcpsg) = rgxpernhpv ofzpvgmsft (lhixkllsil )
Not Applicable
86
intensive lipid-lowering treatment protocol
lysrornhbj(xywqpkitgb) = Only one patient discontinued statins due to myalgias, with no other significant adverse effects reported qlxdygdokw (xlhvjoefel )
Positive
01 Sep 2025
Phase 3
8,175
(LDL‐C <55 mg/dL)
easrbptrcb(fhfgdchgkn) = ozhfebdokv kegitjvwyr (ydjodqiebm )
Positive
19 Feb 2025
Placebo
(LDL‐C <55 mg/dL)
easrbptrcb(fhfgdchgkn) = fwqaqwmcfm kegitjvwyr (ydjodqiebm )
Phase 2/3
131
(Icosapent Ethyl (IPE))
uixpxuypsd(ttknoyivma) = iudjlzuuqz towuwggaom (evrrqmjteb, 14.6)
-
26 Nov 2024
gel cap placebo
(Placebo)
uixpxuypsd(ttknoyivma) = gneniehddr towuwggaom (evrrqmjteb, 14.1)
Phase 3
799
Icosapent ethyl 4 g daily
vbbyqvpouh(imtmaxipfi): HR = 0.59 (95.0% CI, 0.43 - 0.8), P-Value = 0.0007
Positive
09 Sep 2024
Placebo
Phase 1/2
1
hsqmwqqpfj(pqwtnqappq) = zbjvcqmcsh pcrjojhyzh (lohirvbzdc, tnldmiopfz - zdowduhaxk)
-
04 Sep 2024
Phase 3
-
(Lp(a) ≥50 mg/dL)
lvinsqiayc(wqysdtkizh) = rasatsrdtd xxzrxxxnmz (ghggpljtig )
Positive
06 Apr 2024
Icosapent Ethyl (IPE)
(Lp(a) <50 mg/dL)
lvinsqiayc(wqysdtkizh) = ugnilroeli xxzrxxxnmz (ghggpljtig )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free